Stem Cell Therapy Offers Hope for Parkinson’s Disease Patients

A groundbreaking clinical trial is underway, offering a potential recent avenue for treating Parkinson’s disease. Researchers are implanting lab-grown stem cells directly into the brains of patients, aiming to restore dopamine production and alleviate the debilitating symptoms of this progressive neurological disorder.

Understanding Parkinson’s Disease and Dopamine

Parkinson’s disease affects over one million people in the United States, with approximately 90,000 new cases diagnosed annually. The condition is characterized by the gradual loss of dopamine-producing neurons in the brain, leading to tremors, muscle stiffness, and slowed movement. Dopamine is a crucial neurotransmitter responsible for controlling movement, mood, memory, and other essential functions.

Currently available medications and therapies can manage symptoms, but no treatment has been proven to halt or reverse the disease’s progression.

The Stem Cell Therapy Approach

Researchers at Keck Medicine of USC are leading a clinical trial utilizing a novel approach: implanting induced pluripotent stem cells (iPSCs) into the brain. Unlike embryonic stem cells, iPSCs are created by reprogramming adult cells – such as those from skin or blood – into a versatile state, allowing them to develop into various cell types within the body.

“We believe that these iPSCs can reliably mature into dopamine-producing brain cells, and offer the best chance of jump-starting the brain’s dopamine production,” said Xenos Mason, MD, a neurologist specializing in Parkinson’s disease at Keck Medicine and co-principal investigator of the study.

The Surgical Procedure and Monitoring

The implantation procedure involves creating a small opening in the skull to access the basal ganglia, the brain region responsible for movement coordination. Using magnetic resonance imaging (MRI) for precise guidance, neurosurgeon Brian Lee, MD, PhD, carefully places the stem cells into the targeted area.

Following the surgery, participants are closely monitored for 12 to 15 months to assess symptom changes and identify any potential side effects, such as dyskinesia (excessive movements) or infection. Researchers plan to continue monitoring patients for up to five years.

Clinical Trial Details and FDA Designation

The multisite clinical trial, known as REPLACE™, includes 12 participants with moderate to moderate-severe Parkinson’s disease. Keck Medicine is one of three sites in the United States participating in the study. The stem cell therapy, RNDP-001, is developed by Kenai Therapeutics, a biotechnology company focused on neurological disorder treatments.

The U.S. Food and Drug Administration (FDA) has granted the clinical trial rapid-track designation, expediting the development and review process.

Looking Ahead

“Our ultimate goal is to pioneer a technique that can repair patients’ motor function and offer them a better quality of life,” said Dr. Lee. This clinical trial represents a significant step forward in the search for effective treatments for Parkinson’s disease, offering hope for improved outcomes and a better future for those living with this challenging condition.